Swiss National Bank Has $2.21 Million Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Swiss National Bank increased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 6.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 189,700 shares of the company’s stock after buying an additional 10,700 shares during the quarter. Swiss National Bank owned 0.19% of Intellia Therapeutics worth $2,212,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in NTLA. Capstone Investment Advisors LLC increased its holdings in shares of Intellia Therapeutics by 1.4% in the third quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock worth $1,256,000 after acquiring an additional 831 shares in the last quarter. Franklin Resources Inc. increased its stake in Intellia Therapeutics by 10.3% during the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock worth $320,000 after purchasing an additional 1,538 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Intellia Therapeutics by 14.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company’s stock worth $157,000 after buying an additional 1,582 shares during the period. Arizona State Retirement System lifted its stake in Intellia Therapeutics by 6.1% in the fourth quarter. Arizona State Retirement System now owns 28,006 shares of the company’s stock valued at $327,000 after buying an additional 1,615 shares in the last quarter. Finally, E Fund Management Co. Ltd. boosted its holdings in shares of Intellia Therapeutics by 10.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company’s stock valued at $210,000 after buying an additional 1,634 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 29,000 shares of company stock valued at $352,551 in the last quarter. 3.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on NTLA shares. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a report on Monday, March 3rd. Oppenheimer dropped their price target on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. Citigroup upped their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Wells Fargo & Company cut their target price on Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Finally, Wedbush reaffirmed a “neutral” rating and set a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.56.

Intellia Therapeutics Trading Up 1.1 %

Shares of NASDAQ NTLA opened at $8.40 on Friday. The company has a market capitalization of $869.54 million, a P/E ratio of -1.54 and a beta of 1.97. Intellia Therapeutics, Inc. has a 12 month low of $8.11 and a 12 month high of $28.23. The stock has a 50 day moving average of $10.01 and a 200-day moving average of $13.90.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.